Skip to main content
Equibles
APLM logo

APLM · Apollomics Inc.

Track APLM — free

Use APLM with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$27.50 -0.52 (-1.84%) At close · Sep 4
Rebalance outlook locked
Market Cap
$79.63M
Shares
2.90M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date Event Type
2024-08-16 August 2024 Corporate Presentation Presentation
2024-08-13 Canaccord Genuity 44th Annual Growth Conference Conference
2024-06-04 ASCO 2024: Efficacy and Safety of Vebreltinib in Patients With Advanced NSCLC Harboring Met-Exon 14-Skipping: Results of 2.5 Year Follow-Up in KUNPENG Event
2024-06-04 ASCO 2024: Efficacy and safety of the vebreltinib in previously treated, IDH mutant high-grade glioma patients with PTPRZ1-MET FUsion GENe (FUGEN): a randomized, multicentre, open-label, phase II/III trial Event
2024-04-10 AACR Annual Meeting 2024: Vebreltinib: A novel brain-penetrating MET kinase inhibitor demonstrates the mechanism of action and pharmacological anti-tumor activity in diverse patient-derived MET-dysregulated tumor models at clinically relevant drug levels Shareholder meeting
2024-04-10 AACR Annual Meeting 2024: Dependence of EGFR-mutant NSCLC on MET as demonstrated by vebreltinib, a novel and selective brain-penetrating MET kinase inhibitor Shareholder meeting
2024-03-28 Apollomics Full Year 2023 Earnings Conference Call Earnings call
2024-02-14 Oppenheimer 34th Annual Healthcare Life Sciences Conference Conference
2023-12-04 2023 IASLC North America Conference on Lung Cancer, December 2023 poster presentation (Vebreltinib Efficacy In METex14 Mutant NSCLC With or Without Concurrent MET Amplification, MET GCN Status Distributions Compared With Public Databases) Conference
2023-10-26 ESMO 2023 oral presentation (Target therapy matched to genomic alterations in patients with recurrent IDH wildtype glioblastoma: a real-life cohort analysis from Veneto Institute of Oncology, Padua, Italy) Presentation
2023-10-23 ESMO 2023 poster presentation (Preliminary Results of Phase II KUNPENG Study of Vebreltinib in Patients (Pts) with Advanced NSCLC Harboring c-MET Alterations) Presentation
2023-09-15 IASLC 2023 World Conference on Lung Cancer, September 2023 poster presentation Conference
2023-09-13 HC Wainwright 25th Annual Global Investment Conference Presentation Conference

Source: https://ir.apollomicsinc.com/

Key facts CIK 1944885 CUSIP G0411D123 13F (30d) 3 filings 3 filers Visit website Investor relations